PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer

Kwee, Robert M.; Marcus, Charles; Sheikhbahaei, Sara; Subramaniam, Rathan M.

doi:10.1016/j.cpet.2014.12.003

Cited by 9 publications

(8 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the detection of malignancy and the evaluation of a tumor response are separate tasks. Changes in 18 F-FDG avidity have been extensively proven to correlate with the tumor response in breast cancer and many other malignancies (24)(25)(26)(27). This prospective clinical trial provided evidence that changes in 18 F-fluciclovine avidity also correlate well with the tumor response in patients with breast cancer (Spearman r, 0.79; P , 0.001).…”

Section: Discussionmentioning

confidence: 54%

Prospective Clinical Trial of ¹⁸F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers

et al. 2016

View full text Add to dashboard Cite

18 F-labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid ( 18 Ffluciclovine) is a leucine analog radiotracer that depicts amino acid transport into cells. 18 F-fluciclovine PET/CT visualizes malignancy, including prostate cancer, invasive ductal breast cancer, and invasive lobular breast cancer. Whether changes in 18 F-fluciclovine avidity reflect changes in tumor burden resulting from treatment has not been shown. In this prospective clinical trial (clinical trials.gov: NCT01864083), changes in 18 F-fluciclovine avidity after neoadjuvant therapy were compared to breast cancer therapy response, as determined by residual tumor burden on pathology, were evaluated. Methods: Twenty-four women with a new diagnosis of locally advanced invasive ductal breast cancer (n 5 18) or invasive lobular breast cancer (n 5 6) underwent 18 F-fluciclovine PET/CT before and after the completion of neoadjuvant systemic therapy. SUV max , SUV mean , metabolic tumor volume, and total lesion avidity were obtained for the primary breast tumor, axillary lymph nodes, and extraaxillary lymph nodes on each examination and corrected for background 18 F-fluciclovine avidity. The relationship between changes in 18 F-fluciclovine avidity and the percentage of reduction of tumor on pathology was assessed with the Spearman rank correlation. Results: The median decrease in the corrected SUV max of the primary breast lesions was 99% (range, 33%-100%). The median reduction of tumor on pathology was 92% (range, 10%-100%). Changes in 18 F-fluciclovine avidity were strongly correlated with the percentage of reduction of tumor on pathology (Spearman r, 0.79; 95% CI, 0.56-0.90; P , 0.001). Conclusion: Changes in 18 F-fluciclovine avidity strongly correlated with the tumor response on pathology in this pilot study.

show abstract

Section: Discussionmentioning

confidence: 54%

Prospective Clinical Trial of ¹⁸F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers

et al. 2016

View full text Add to dashboard Cite

show abstract

“…However, given that cervical oesophageal adenocarcinoma is extremely rare the experts agreed that only CT scans of the chest and abdomen are required to inform the treatment of patients with oesophageal adenocarcinoma. However, EUS has been shown to be superior to CT in detecting lymph node metastases and PET scans are more accurate than CT scans in the detection of distant metastases [21][22][23][24][25]. All 12 Asian experts accepted completely 'recommendations 3d and 3e' once they had been reworded and combined into a new revised 'recommendation 3d' [A ¼ 100%].…”

Section: Resultsmentioning

confidence: 99%

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

et al. 2019

View full text Add to dashboard Cite

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of oesophageal cancer was published in 2016, and covered the management and treatment of local/ locoregional disease, limited disease, locally advanced disease and the management of advanced/metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic oesophageal cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

show abstract

“…According to this paper, the response of parameters of PET/CT also plays a positive role in the prognosis. Especially for patients with locally advanced disease, continuing neoadjuvant chemotherapy may be beneficial if they respond well; however, if a patient responds poorly or weakly to neoadjuvant radiotherapy and chemotherapy, that treatment should be stopped as soon as possible [46][47]. This is of great value to therapeutic economics.…”

Section: Discussionmentioning

confidence: 99%

Using 18F-FDG PET/CT to Predict Esophageal Cancer Survival: A Meta-Analysis

Wang¹,

Song²,

S³

2021

austinjradiol

View full text Add to dashboard Cite

Purpose: This study aimed to explore whether metabolic responses to 18F-fluorodeoxyglucose positron emission tomography/computed tomography collected before, during, or after the treatment can predict the long-term survival rate of patients with esophageal cancer. Patients and Methods: We searched for the following indices in articles listed in English and Chinese literature databases: the maximum standard uptake value (SUVmax), mean standard uptake value (SUVmean), Metabolic Tumor Volume (MTV), and Total Lesion Glycolysis (TLG). If their values exceeded the thresholds, we defined them as responders; if they did not, we defined them as non-responders. We then performed a meta-analysis by extracting the Hazard Ratio (HR) and 95% confidence interval (95% CI) from each report to predict whether the status of responder or non-responder had an impact on prognosis. Results: We identified 34 articles with a combined sample size of 2794 patients. HRs and 95% CIs were measured as follows: SUVmax = 1.15 (0.98- 1.35), MTV = 3.45 (0.78-15.25), TLG = 1.04 (1.02-1.07), and SUVmean = 1.85 (1.33-2.57) (before treatment); ΔSUVmax = 1.22 (1.06-1.39), Δ MTV = 1.07 (0.54- 2.15), and ΔTLG = 1.09 (0.59-2.02) (during treatment); and SUVmax = 1.13 (1.05- 1.22) and TLG = 1.05 (1.02-1.09) (after treatment). The results showed that the overall survival of the patients with low SUV (MTV, TLG) values was significantly higher than that of the patients with high SUV (MTV, TLG) values. Conclusions: This meta-analysis shows that the prognoses of patients with PET metabolic responses are significantly better than those of non-responders. Our findings may help inform the clinical treatment and prediction of the prognoses of patients with esophageal cancer.

show abstract

PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer

Cited by 9 publications

References 51 publications

Prospective Clinical Trial of ¹⁸F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers

Prospective Clinical Trial of ¹⁸F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Using 18F-FDG PET/CT to Predict Esophageal Cancer Survival: A Meta-Analysis

Contact Info

Product

Resources

About

PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer

Cited by 9 publications

References 51 publications

Prospective Clinical Trial of 18F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers

Prospective Clinical Trial of 18F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Using 18F-FDG PET/CT to Predict Esophageal Cancer Survival: A Meta-Analysis

Contact Info

Product

Resources

About

Prospective Clinical Trial of ¹⁸F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers

Prospective Clinical Trial of ¹⁸F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers